Potential risks of GLP antibodies?

[deleted.user.16]

We heard about sterility fails, we heard about endotoxin scares. One thing I've read about on other social media but surprisingly have not seen here are the risks that might come with developing antibodies to GLP meds. We know from the Retatrutide trials that a significant amount of people developed antibodies to it (from 4% of the people on 1mg to 18% in the 12mg group). And that's from the "legit" trial drugs; the drugs we are jabbing could possibly be significantly more degraded because of questionable manufacturing/shipping/storage methods from grey vendors and could result in even more antibodies.

The theory that I have heard is that these antibodies could not only neutralize our precious Chinese peptides but also bind our own GLP-1 hormones produced by our own bodies. This theory is based on many actual cases of this happening in the 90s with epoetin alfa (rHuEPO), a hormone used to stimulate production of red blood cells and also injected subcutaneously. Improper storage and handling (possibly from chemicals in the rubber stoppers in pre-filled syringes reacting with the protein) caused aggregation/degradation, causing the patients to produce antibodies that attack both the injected protein and the patient's own hormone.

PRCA [Pure red cell aplasia] occurs from the generation of antibodies against rHuEPO, which neutralize not only the recombinant protein, but also native erythropoietin, resulting in the absence of red cell precursors in the bone marrow.

https://pubmed.ncbi.nlm.nih.gov/15792922/

I have not been able to find any follow-up information about how this was resolved for the patients (if the antibodies went away after stopping the drug or if these people needed blood transfusions regularly for the rest of their lives).

Now, I don't think the theoretical effects of GLP-1 antibodies would be nearly as dangerous as the effects of erythropoietin antibodies. Nobody would need blood transfusions; I think you would just be really hungry if you were low on GLP-1? What GIP or glucagon antibodies would theoretically do, I won't even attempt to speculate on because I have no idea.

If antibodies are at all a risk, it would really change the risk-to-reward calculation for a lot of people (like me) who are overweight or borderline obese, and do not plan to be GLP "lifers." At the very least, I wonder if it would be safer to switch from Reta to Tirz or Sema (more stable peptides) and start buying smaller vials to reduce the amount of time that the peptide sits after reconstitution.

I'm curious what the forum thinks. Does anyone have more info on this? I know a few of y'all have some medical and/or chemistry background so I'd be especially interested in your opinions.

 

[IvanD]

Thanks for the information. I do not have an opinion on the matter but very curious to learn more from people smarter than myself.

 

[Jfrick11]

We heard about sterility fails, we heard about endotoxin scares. One thing I've read about on other social media but surprisingly have not seen here are the risks that might come with developing antibodies to GLP meds. We know from the Retatrutide trials that a significant amount of people developed antibodies to it (from 4% of the people on 1mg to 18% in the 12mg group). And that's from the "legit" trial drugs; the drugs we are jabbing could possibly be significantly more degraded because of questionable manufacturing/shipping/storage methods from grey vendors and could result in even more antibodies.

View attachment 21068

The theory that I have heard is that these antibodies could not only neutralize our precious Chinese peptides but also bind our own GLP-1 hormones produced by our own bodies. This theory is based on many actual cases of this happening in the 90s with epoetin alfa (rHuEPO), a hormone used to stimulate production of red blood cells and also injected subcutaneously. Improper storage and handling ( possibly from chemicals in the rubber stoppers in pre-filled syringes reacting with the protein ) caused aggregation/degradation, causing the patients to produce antibodies that attack both the injected protein and the patient's own hormone.

https://pubmed.ncbi.nlm.nih.gov/15792922/

I have not been able to find any follow-up information about how this was resolved for the patients (if the antibodies went away after stopping the drug or if these people needed blood transfusions regularly for the rest of their lives).

Now, I don't think the theoretical effects of GLP-1 antibodies would be nearly as dangerous as the effects of erythropoietin antibodies. Nobody would need blood transfusions; I think you would just be really hungry if you were low on GLP-1? What GIP or glucagon antibodies would theoretically do, I won't even attempt to speculate on because I have no idea.

If antibodies are at all a risk, it would really change the risk-to-reward calculation for a lot of people (like me) who are overweight or borderline obese, and do not plan to be GLP "lifers." At the very least, I wonder if it would be safer to switch from Reta to Tirz or Sema (more stable peptides) and start buying smaller vials to reduce the amount of time that the peptide sits after reconstitution.

I'm curious what the forum thinks. Does anyone have more info on this? I know a few of y'all have some medical and/or chemistry background so I'd be especially interested in your opinions.

Somw people do develop antibodies to GLP1s, that’s normal with peptide drugs. This has been seen across trials for basically all peptide biologics

Rates vary (like the 4–18% mentioned for retatrutide)

But here’s the key part people miss:

In the vast majority of cases, these antibodies are:

Low titer

Non-neutralizing

Clinically irrelevant

Meaning: they show up on labs but don’t actually block the drug or cause harm.

Very rarely (but it can happen), there are cases where antibodies reduce drug effectiveness over time.

That looks like:

“It stopped working”

Blunted appetite suppression

Less glucose control

But even here:

It’s uncommon

It doesn’t usually affect your natural GLP1

The comparison to Epoetin alfa causing Pure red cell aplasia is a pretty big leap. That was a very specific situation involving protein instability and formulation issues, and it led to a rare but serious immune response. GLP meds are much smaller, engineered differently, and so far no one is seeing evidence of people developing antibodies that attack their own natural GLP-1.

Where I do think the concern is fair is around product quality. Peptides that are mishandled.... heat, agitation, sitting too long after reconstitution, can degrade or aggregate, and that could increase the chance of immune reactions or just make them less effective.

So for me, the risk calculation isn’t really “will my body attack itself,” it’s more about consistency and quality of what you’re using.

 

[deleted.user.16]

Thanks for answering. I know Semaglutide has been around for a couple of decades, and by now millions of people have used GLP meds at this point and it's certainly reassuring that no one's reported any horrible damage to their bodies.

 

[deleted.user.16]

Though I did do more probing and apparently Tirzep can cause neutralizing antibodies for both GLP-1 and GIP in around 2% of people, and cross-reactive antibodies (ones that attack your own hormones) in less than 1% of people. But then the study also said that these antibodies did not affect drug efficacy and only seemed to cause injection site welts, so it might not be a huge deal.

Results​
TE ADA [treatment-emergent antidrug antibodies] developed in 51.1% of tirzepatide-treated patients. Proportions were similar across dose groups. Maximum ADA titers ranged from 1:20 to 1: 81 920 among TE ADA+ patients. Neutralizing antibodies (NAb) against TZP activity on GIP and GLP-1 receptors were observed in 1.9% and 2.1% of patients, respectively. Less than 1.0% of patients had cross-reactive NAb against nGIP or nGLP-1. TE ADA status, ADA titer, and NAb status had no effect on the pharmacokinetics or efficacy of TZP. More TE ADA+ patients experienced hypersensitivity reactions or injection site reactions than TE ADA– patients. The majority of hypersensitivity and injection site reactions were nonserious and nonsevere, and most events occurred and/or resolved irrespective of TE ADA status or titer.

https://pmc.ncbi.nlm.nih.gov/articles/PMC10795913/

 

[Jfrick11]

Though I did do more probing and apparently Tirzep can cause neutralizing antibodies for both GLP-1 and GIP in around 2% of people, and cross-reactive antibodies (ones that attack your own hormones) in less than 1% of people. But then the study also said that these antibodies did not affect drug efficacy and only seemed to cause injection site welts, so it might not be a huge deal.

https://pmc.ncbi.nlm.nih.gov/articles/PMC10795913/

That’s pretty consistent with what’s been seen with Tirzepatide.

Yes.... there are:

Neutralizing antibodies in a small % of people

Even rarer cross-reactive antibodies (binding to native GLP-1/GIP)

But the important part is what happens clinically—and in trials:

They didn’t meaningfully impact efficacy

They weren’t associated with systemic issues

Most of the time, the only signal was mild injection site reactions

So while cross-reactive antibodies sounds scary on paper, it hasn’t translated into real world problems like hormone deficiency or anything resembling what happened with Epoetin alfa.

Also worth noting:

These studies are on regulated, properly manufactured drug

So they likely represent a worst case baseline immune response, not zero risk

If anything, it reinforces that:

even when antibodies do form, they’re usually not clinically meaningful

 

[RetCurious]

Where I do think the concern is fair is around product quality. Peptides that are mishandled.... heat, agitation, sitting too long after reconstitution, can degrade or aggregate, and that could increase the chance of immune reactions or just make them less effective.

So for me, the risk calculation isn’t really “will my body attack itself,” it’s more about consistency and quality of what you’re using.

Filed under "Risk Tolerance Guidelines", thank you.